Ascendis Pharma (ASND) Stock Forecast and Price Target (2026)

The average target of $307.26 sits well above the $226.86 price, +35.4%. The median is $313.97, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

The published targets span $263.55 to $351.64. That gap is 29% of the average target, which counts as narrow disagreement. A spread that tight means the analysts broadly agree on the model, so the consensus is a reasonably stable read rather than an average of wildly different views.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the ASND is it a buy page.

In the last six months there have been 2 raises and 5 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

Of the analysts with a published rating, 20 say buy, 0 say hold, and 0 say sell, so 100% carry a buy. That mix has been broadly steady over the last three months.

Read the distribution rather than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

• It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
• The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
• Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
• Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering ASND do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

On the figures we hold as of October 2026, ASND trades at about 17.7 times trailing earnings and 20.8 times forward earnings. A forward multiple at or above the trailing one means the market is not pricing in earnings growth over the next year, which is worth understanding before assuming a long-horizon rise.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Ascendis Pharma can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are YORVIPATH is carrying the model, YUVIWEL opens a second large launch, Platform reuse lowers the cost of the next program. The risk cited most often against it is revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ASND is it a buy page. This page deliberately stops at the numbers.